TRW & Co · Trade, Regulation & ESG
Healthcare Regulation in Singapore
Healthcare regulation in Singapore licenses services rather than buildings, so every new service, site, vehicle or remote channel is a licensing question. MOH, HSA and the professional councils each regulate a different layer: services, products and practitioners. This guide explains the Healthcare Services Act framework, product rules, key decisions and the evidence regulators expect in 2026.
Key pointUnder the Healthcare Services Act, approval attaches to a licensable service and a mode of delivery, so a licensed clinic is not automatically approved for home visits, mobile units or video consultations; each needs its own approval before launch.
At a glance
Services, not premises
The Healthcare Services Act 2020 replaced the Private Hospitals and Medical Clinics Act, licensing providers for the services and modes they offer rather than buildings.
Sixteen licensable services
MOH licenses 16 services, from acute hospitals and nursing homes to outpatient medical and dental, laboratories, radiology, dialysis and ambulance services.
Mode approvals are separate
Permanent premises, temporary premises, conveyance and remote delivery each need approval for each service, and specified services need separate approval too.
Key appointment holders
Every licensee needs a Principal Officer, and selected services need a Clinical Governance Officer; licences generally run for two years.
HSA regulates products
Medicines, medical devices and clinical trials fall under HSA, with device registration and dealer licensing scaled to risk from Class A to Class D.
Swipe or scroll →
What healthcare regulation in Singapore covers
Healthcare regulation in Singapore governs who may provide healthcare services, which products may be supplied, who may practise, how patient information is handled, what may be advertised and how research is conducted. It applies to hospitals and clinics, but also to laboratories, ambulance and medical transport operators, nursing homes, telemedicine platforms, pharmaceutical and device companies, and investors who acquire any of them.
Three regulators carry most of the load. The Ministry of Health (MOH) licenses healthcare services. The Health Sciences Authority (HSA) regulates health products, including medicines, medical devices and clinical trials. Professional councils, such as the Singapore Medical Council, register and discipline practitioners. A single business often deals with all three, plus the Personal Data Protection Commission for patient data.
The question usually becomes legal when a provider launches a new service, site or channel; when an investor buys a healthcare business; when a product is brought to market; when a practitioner is recruited from overseas; or when something goes wrong with a patient, a product or an advertisement.
The legal and regulatory framework
The Healthcare Services Act 2020
The Healthcare Services Act 2020 (HCSA) is the centrepiece. It replaced the Private Hospitals and Medical Clinics Act and moved Singapore from a premises-based model to a services-based one: providers are licensed for the services they offer and the modes in which they deliver them, not just for a building. MOH implemented the Act in phases between 2022 and the end of 2023. MOH's regulation and licensing page and the HCSA portal set out the framework.
There are 16 licensable healthcare services, ranging from acute hospital, community hospital and nursing home services to outpatient medical, outpatient dental, clinical laboratory, radiological, nuclear medicine, renal dialysis, assisted reproduction, blood banking, cord blood banking, human tissue banking, ambulatory surgical centre, emergency ambulance and medical transport services.
Each service may be delivered through approved modes: permanent premises, temporary premises, conveyance and remote delivery. Approval for one mode does not extend to another. Within each service, certain higher-risk activities are specified services, such as endoscopy, liposuction, radiation oncology and dental cone beam CT, and they need separate MOH approval before they are offered. Offering a specified service without approval is an offence.
The Act also formalises key appointment holders. Every licensee needs a Principal Officer, and selected services need a Clinical Governance Officer, whose suitability and duties are set out in MOH's codes of practice. Licences generally run for two years, and MOH expects renewal applications at least two months before expiry.
| Element | What it means | Practical consequence |
|---|---|---|
| Licensable healthcare service | One of 16 defined services under the HCSA | Classify each activity by what is done, not by its marketing label |
| Mode of service delivery | Permanent premises, temporary premises, conveyance or remote | Each mode needs its own approval for each service |
| Specified service | Higher-risk activity within a licensable service | Separate MOH approval before it is offered |
| Principal Officer | Key appointment holder for every licensee | Must be appointed and suitable before licensing |
| Clinical Governance Officer | Required for selected services | Accountable for clinical governance arrangements |
| Licence tenure | Generally two years | Renew at least two months before expiry |
Health products and HSA
The Health Products Act 2007 and the Medicines Act 1975 give HSA its powers over health products. Therapeutic products need product registration before supply, and importers, wholesalers and manufacturers need dealer licences. Medical devices are classified by risk from Class A to Class D, with registration and dealer licensing requirements scaled to risk; software as a medical device falls within the same framework. HSA also regulates clinical trials of therapeutic products and medicinal products, and advertising of medicinal products, while medical device trials are governed by the Human Biomedical Research Act.
Professionals, research and public health
Doctors must be registered with the Singapore Medical Council under the Medical Registration Act 1997, with parallel regimes for dentists, nurses, pharmacists and allied health professionals. Overseas-trained doctors may obtain conditional registration subject to supervision. Human biomedical research is governed by the Human Biomedical Research Act 2015, administered by MOH with its own framework for institutional review boards and consent. The Infectious Diseases Act 1976 imposes notification and control duties, and the Personal Data Protection Act 2012 applies to patient data alongside professional confidentiality.
Key decisions for providers and investors
Most problems with healthcare regulation in Singapore arise from decisions taken before anyone looked at the licence. The six decisions below deserve legal input from the start.
Classifying the service
Describe the activity, who performs it and for whom, then map it to a licensable service and any specified services. A wellness or screening label does not take clinical activity outside scope.
Choosing the modes
Decide early whether care will be delivered at premises, at temporary sites, in vehicles or remotely, because each needs approval and its own policies, equipment and records.
Choosing the licensee entity
The licensee carries legal responsibility. In group structures, decide which company holds each licence, and align it with employment, leases and contracts before applying.
Appointing key officers
Identify the Principal Officer and any Clinical Governance Officer early. Their suitability is part of the regulator's review, and late changes delay approval.
Products in the service
Medicines, devices and software used in care bring HSA requirements. Check product registration, dealer licensing and any import controls before procurement.
Advertising and patient information
Service advertising is governed by the Healthcare Services (Advertisement) Regulations 2021, and product advertising by HSA rules. Plan campaigns around both.
Under a services-based regime, every new channel is a licensing question. Treat it as one before the launch date is announced, not after.
Patient data, records and healthcare regulation in Singapore
Patient information sits under several overlapping rules. The Personal Data Protection Act 2012 governs collection, use, disclosure, protection and transfer of personal data, including breach notification to the PDPC and affected individuals where thresholds are met. Professional ethical codes impose confidentiality duties on practitioners. Licence conditions and codes of practice under the HCSA add requirements on medical records, retention and access.
MOH has also taken forward legislation on health information, including a Health Information Bill intended to require contribution of key data to the National Electronic Health Record and to strengthen cybersecurity and data-sharing safeguards. Providers should track the commencement of these requirements, because they will affect system procurement, consent processes and vendor contracts.
In practice, data problems arise where clinical, marketing and technology teams use patient data for different purposes without a single map of what is collected and why. A data inventory, clear purposes, vendor controls and breach response plans are as much part of healthcare regulation in Singapore as the service licence itself.
Funding, pricing and enforcement
Many providers depend on public financing schemes, such as MediSave, MediShield Life and national primary care programmes, which have their own participation, claims and audit requirements set by MOH. Participation is not automatic with a licence, and claims irregularities are treated seriously. MOH also publishes fee benchmarks for common procedures, which, while not price caps, inform what patients and insurers expect.
Enforcement of healthcare regulation in Singapore ranges from inspection findings and directions to licence conditions, suspension, revocation and prosecution. Practitioners face separate disciplinary processes before their professional councils, which can run in parallel with regulatory action against the licensee. Providers should therefore coordinate their response to any incident so that what the licensee tells MOH is consistent with what practitioners tell their council.
Launching or expanding a service: step by step
The sequence below suits a new provider or an existing provider adding a service, site or channel. Timelines vary with the service and the readiness of documents, so build the licence into the critical path rather than the final week.
- Describe and classify. Write a short description of each activity, then classify it against the 16 licensable services, the specified services and the modes of delivery, recording the reasoning in a dated note.
- Settle the structure. Confirm the licensee entity, ownership, premises arrangements and key appointment holders, with board resolutions and appointment records.
- Prepare governance documents. Draft clinical governance, infection control, patient safety, records and complaints policies tailored to the service and each mode, rather than adapted from another jurisdiction.
- Check products and people. Verify practitioner registration and supervision arrangements, and confirm that medicines, devices and software used in the service meet HSA requirements.
- Apply through the HCSA portal. Submit the licence and mode applications with supporting documents, and respond promptly to MOH queries or inspection requests.
- Prepare for go-live. Train staff, test record systems, check advertising and patient information against the rules and confirm insurance cover before opening.
- Maintain and renew. Track conditions, notify MOH of changes where required, and renew at least two months before expiry.
Documents and evidence regulators expect
MOH and HSA inspections focus on whether documented systems are actually used. Keep the following current and accessible:
- Licences, mode and specified-service approvals, with conditions and renewal dates.
- Appointment records and suitability evidence for the Principal Officer and Clinical Governance Officer.
- Practitioner registration records, supervision plans for conditionally registered staff and training logs.
- Clinical governance, infection control, incident reporting and complaints policies, with version control.
- Medical records systems, retention arrangements and data protection documentation.
- Product registration, dealer licence and supplier records for medicines and devices used.
- Advertising review records showing which regime was applied and who approved each piece.
- Incident and adverse event reports, investigations and corrective actions.
Keep a dated classification note for every service and channel. When MOH asks why an activity was treated as within, or outside, a licensable service or mode, a contemporaneous note citing the Act and MOH materials is the most persuasive answer. It also stops scope from drifting as the business grows and marketing teams rename services.
Risks and common mistakes
Assuming a premises licence covers new channels
Under the HCSA, approval attaches to a service and a mode. A clinic licensed to deliver outpatient medical services at its premises is not automatically approved for home visits, a mobile screening van or video consultations. Providers that launch new channels on the strength of an existing licence risk operating without approval. Treat every new site, vehicle or remote offering as a trigger for a written review, and obtain the necessary approvals before launch. Our telemedicine and digital health team handles remote modes and platform contracts.
Missing a specified service
Specified services are easy to overlook when a service is scoped around its headline category. Adding endoscopy to an outpatient offering, or a new imaging modality to a radiological service, may require separate approval. Because offering a specified service without approval is an offence, build a specified-service check into clinical governance whenever procedures, equipment or practitioner skills change.
Advertising that mixes services and products
Campaigns often promote a service and a product together, with testimonials and links added late. Service elements fall under the Healthcare Services (Advertisement) Regulations 2021; product elements under HSA rules. Approving the whole piece under one regime is a common error. Review each element under the correct rules, and check the joint circular on telemedicine services and advertisements for remote services.
Treating product rules as someone else's problem
Providers sometimes assume that suppliers handle HSA compliance. But importing or supplying unregistered products, or using devices outside their registered purpose, can expose the provider too. Check product registration and dealer licensing before procurement, and include compliance warranties in supply contracts. Our medical device compliance and pharmaceutical commercialisation teams advise on the product side.
Under-estimating diligence in healthcare acquisitions
Licences are not freely transferable assets, and a change in the licensee or key appointment holders may require MOH engagement. Buyers who focus on revenue and leases sometimes miss unapproved modes, expired specified-service approvals, unregistered products or practitioner registration gaps. Diligence should test actual operations against approvals, and transaction documents should address licence continuity, conditions precedent and specific indemnities.
Treating data projects as outside research rules
Providers and digital health companies increasingly want to use clinical data or tissue to develop products, train algorithms or publish findings. Depending on what is done, the Human Biomedical Research Act 2015 may require institutional review board approval and specific consent, and the PDPA will apply to any personal data involved. Calling a project quality improvement or analytics does not settle the question. Map the activity against the research definitions early, document the conclusion, and build consent and governance into patient-facing processes before data is collected rather than trying to retrofit them afterwards.
The cross-border angle
Healthcare regulation in Singapore is strictly territorial. Foreign licences, accreditation and product approvals can support an application or a product dossier, but they do not authorise a licensable service or the supply of a health product in Singapore. HSA does operate abridged evaluation routes for therapeutic products already approved by certain reference regulators, which can shorten timelines for products with approvals elsewhere.
For groups with links to Bangladesh, the UK, the UAE or China, the common issues are practitioner mobility, cross-border telemedicine and medical tourism. Overseas-trained doctors need Singapore registration before they practise here, and patients located abroad during a remote consultation may bring foreign rules into play. Referral and marketing arrangements with overseas agents should be reviewed for advertising and inducement issues.
Medical tourism raises its own questions. Providers that accept patients referred from Bangladesh, the Gulf or China should agree in writing who is responsible for pre-arrival information, consent in the patient's language, follow-up care after the patient returns home and payment arrangements. Agents who promise outcomes or package prices on the provider's behalf can create advertising and liability problems in Singapore, so their materials should be approved before use.
Data is a further cross-border issue. Transfers of patient data outside Singapore must meet the PDPA transfer obligations, and some foreign regimes impose their own localisation rules. Our health data governance team coordinates these requirements, and we work with local counsel across TRW & Co's network where a foreign regulator is involved.
How TRW & Co helps
We advise providers, investors, platforms and product companies on healthcare regulation in Singapore. Where Singapore court or tribunal representation is required, we work alongside Singapore-qualified counsel.
Licensing strategy
We classify services, modes and specified services under the HCSA, settle licensee structures and key appointments, and prepare applications with your clinical team.
Product pathway
We map HSA registration, dealer licensing, advertising and clinical trial requirements, working with our clinical research agreements team where studies are involved.
Transactions
We run regulatory diligence on healthcare acquisitions and investments and draft provisions on licence continuity, conditions and indemnities.
Compliance and incidents
We review advertising, records and governance, and support responses to MOH or HSA inquiries, coordinating with our healthcare disputes and professional regulation teams where needed.
See our practices for related services, or contact us to discuss a launch, acquisition or regulatory query.
Checklist for decision-makers
- Has every activity been classified against the 16 licensable services, with a dated note?
- Does each service have approval for every mode we use, including remote and conveyance?
- Have specified services been identified and approved before they are offered?
- Are the Principal Officer and any Clinical Governance Officer appointed and documented?
- Are all practitioners properly registered, with supervision plans where conditions apply?
- Do the medicines, devices and software we use meet HSA registration and dealer requirements?
- Is every advertisement reviewed under the correct service or product rules?
- Is renewal tracked, with applications made at least two months before expiry?
Organisations that can answer yes to each question are well placed to grow within the rules and to answer regulators confidently. Healthcare regulation in Singapore rewards providers who plan licensing as carefully as they plan clinical care.
Frequently asked questions
01Do we need a licence to open a clinic in Singapore?
Yes. Outpatient medical and outpatient dental services are licensable healthcare services under the Healthcare Services Act 2020, so the provider needs an MOH licence for the service and approval for each mode of delivery it will use. Specified services within the licence need separate approval. The licensee must appoint a Principal Officer, and some services need a Clinical Governance Officer. Apply through the HCSA portal and build the licence into the project timeline.
02Can we add telemedicine to our existing clinic licence?
Remote delivery is a separate mode, so you need approval for it in respect of the relevant licensable service before offering video or other remote consultations. Professional standards still apply, and MOH and the professional bodies have issued joint guidance on telemedicine services and advertising. Define which presentations are clinically suitable for remote care, how escalation to in-person review works, and how records and data are handled on the platform.
03What are specified services?
They are higher-risk or complex activities within a licensable healthcare service, such as endoscopy, liposuction, radiation oncology or dental cone beam CT. Each needs MOH approval before it is offered, even if the provider already holds the main service licence. Offering a specified service without approval is an offence. Check the current list whenever you add procedures, equipment or practitioner capabilities.
04Do medical devices need HSA approval before we use them?
Generally, medical devices supplied in Singapore must meet HSA's requirements, which depend on risk classification from Class A to Class D. Higher-risk devices require product registration, and importers, manufacturers and wholesalers need dealer licences. Software can be a medical device. Providers should confirm that devices they buy are properly registered and supplied by licensed dealers, and include compliance warranties in supply contracts.
05Can a foreign doctor practise in our Singapore clinic?
Only after registration with the Singapore Medical Council under the Medical Registration Act 1997. Overseas-trained doctors from recognised institutions may be eligible for conditional registration, which usually requires supervised practice for a period. The clinic should verify registration status before rostering, put a supervision plan in place where conditions apply, and also deal with the work pass requirements for foreign practitioners.
06Is a healthcare licence transferred when we buy a clinic business?
Licences are not freely transferable assets. Whether MOH must be notified or a new licence obtained depends on how the transaction is structured, for example a share purchase rather than an asset purchase, and on changes to key appointment holders. Diligence should test actual operations against approvals. The sale agreement should address licence continuity, MOH engagement and conditions precedent before completion.
07How is healthcare advertising regulated?
Advertising of licensable healthcare services is governed by the Healthcare Services (Advertisement) Regulations 2021 under the HCSA, which set rules on content, presentation and matters such as testimonials. Advertising of medicinal products and other health products falls under HSA rules. Campaigns that mix services and products need both regimes applied to the relevant elements. Keep review records showing who approved each piece and under which rules.
Sources and official materials
- MOH: Healthcare services regulation and licensing — Overview of the HCSA licensing framework
- HCSA portal: About the Healthcare Services Act — Licensable services, modes, specified services and key roles
- Health Products Act 2007 — Regulation of health products and dealers
- HSA: Medical devices regulatory overview — Risk classes, registration and dealer licensing
- HSA: Therapeutic products overview — Product registration and dealer requirements for medicines
- Medical Registration Act 1997 — Registration and discipline of doctors
- MOH: Regulation of human biomedical research — Research governance and consent framework
General information only, current as at 20 October 2026. It is not legal advice and does not create a lawyer–client relationship. Singapore law and regulatory practice change; check current official sources and take advice on the facts of your matter.
Talk it through
before you decide.
Share the decision, the jurisdictions and the timetable. A partner will tell you what matters, what can wait and what it will take.